Epidermal growth factor receptor variants in patients from Myanmar with lung adenocarcinoma

[1]World Health Organization. Cancer; 2018 [cited 2019 Aug 07]; Available from: http://www.who.int/news-room/fact-sheets/detail/cancerWorld Health OrganizationCancer2018[cited 2019 Aug 07]; Available from: http://www.who.int/news-room/fact-sheets/detail/cancerSearch in Google Scholar

[2]World Health Organization. Cancer country profiles 2014. [cited 2019 Aug 07]; Available from: http://www.who.int/cancer/country-profiles/en/World Health OrganizationCancer country profiles 2014[cited 2019 Aug 07]; Available from: http://www.who.int/cancer/country-profiles/en/Search in Google Scholar

[3]Fang S, Wang Z. EGFR mutations as a prognostic and predictive marker in non-small-cell lung cancer. Drug Des Dev Ther. 2014; 8:1595–611.FangSWangZEGFR mutations as a prognostic and predictive marker in non-small-cell lung cancerDrug Des Dev Ther20148159561110.2147/DDDT.S69690Search in Google Scholar

[4]Sgambato A, Casaluce F, Maione P, Rossi A, Rossi E, Napolitano A, et al. The role of EGFR tyrosine kinase inhibitors in the first-line treatment of advanced non small cell lung cancer patients harboring EGFR mutation. Curr Med Chem, 2012; 19:3337–52.SgambatoACasaluceFMaionePRossiARossiENapolitanoAThe role of EGFR tyrosine kinase inhibitors in the first-line treatment of advanced non small cell lung cancer patients harboring EGFR mutationCurr Med Chem20121933375210.2174/092986712801215973Search in Google Scholar

[5]Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, et al.; North-East Japan Study Group. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010; 362:2380–8.MaemondoMInoueAKobayashiKSugawaraSOizumiSIsobeHNorth-East Japan Study GroupGefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFRN Engl J Med20103622380810.1056/NEJMoa0909530Search in Google Scholar

[6]Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, et al.; West Japan Oncology Group. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 2010; 11:121–8.MitsudomiTMoritaSYatabeYNegoroSOkamotoITsurutaniJWest Japan Oncology GroupGefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trialLancet Oncol201011121810.1016/S1470-2045(09)70364-XSearch in Google Scholar

[7]Sequist LV, Yang JC, Yamamoto N, O’Byrne K, Hirsh V, Mok T, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013; 31:3327–34.SequistLVYangJCYamamotoNO’ByrneKHirshVMokTPhase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutationsJ Clin Oncol20133133273410.1200/JCO.2012.44.280623816960Search in Google Scholar

[8]Little J, Higgins JP, Ioannidis JP, Moher D, Gagnon F, von Elm E, et al. STrengthening the REporting of Genetic Association Studies (STREGA)—an extension of the STROBE statement. Genet Epidemiol. 2009; 33:581–98.LittleJHigginsJPIoannidisJPMoherDGagnonFvon ElmESTrengthening the REporting of Genetic Association Studies (STREGA)—an extension of the STROBE statementGenet Epidemiol2009335819810.1093/acprof:oso/9780195398441.003.0010Search in Google Scholar

[9]Roche Molecular Systems. cobas EGFR Mutation Test (v1); 2013 April [cited 2019 Aug 07]. Available from: https://www.accessdata.fda.gov/cdrh_docs/pdf12/P120019c.pdfRoche Molecular Systemscobas EGFR Mutation Test (v1)2013April[cited 2019 Aug 07]. Available from: https://www.accessdata.fda.gov/cdrh_docs/pdf12/P120019c.pdfSearch in Google Scholar

[10]Midha A, Dearden S, McCormack R. EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII). Am J Cancer Res. 2015; 5:2892–911.MidhaADeardenSMcCormackREGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII)Am J Cancer Res201552892911Search in Google Scholar

[11]Shi Y, Li J, Zhang S, Wang M, Yang S, Li N, et al. Molecular epidemiology of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology – mainland China subset analysis of the PIONEER study. PLoS One. 2015; 10:e0143515. doi: 10.1371/journal.pone.0143515ShiYLiJZhangSWangMYangSLiNMolecular epidemiology of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology – mainland China subset analysis of the PIONEER studyPLoS One201510e014351510.1371/journal.pone.0143515465788226599344Open DOISearch in Google Scholar

[12]Li AR, Chitale D, Riely GJ, Pao W, Miller VA, Zakowski MF, et al. EGFR mutations in lung adenocarcinomas: clinical testing experience and relationship to EGFR gene copy number and immunohistochemical expression. J Mol Diagn. 2008; 10:242–8.LiARChitaleDRielyGJPaoWMillerVAZakowskiMFEGFR mutations in lung adenocarcinomas: clinical testing experience and relationship to EGFR gene copy number and immunohistochemical expressionJ Mol Diagn200810242810.2353/jmoldx.2008.070178232978918403609Search in Google Scholar

[13]Kobayashi S, Canepa HM, Bailey AS, Nakayama S, Yamaguchi N, Goldstein MA, et al. Compound EGFR mutations and response to EGFR tyrosine kinase inhibitors. J Thorac Oncol. 2013; 8:45–51.KobayashiSCanepaHMBaileyASNakayamaSYamaguchiNGoldsteinMACompound EGFR mutations and response to EGFR tyrosine kinase inhibitorsJ Thorac Oncol20138455110.1097/JTO.0b013e3182781e35353104323242437Search in Google Scholar

[14]Tam IY, Leung EL, Tin VP, Chua DT, Sihoe AD, Cheng LC, et al. Double EGFR mutants containing rare EGFR mutant types show reduced in vitro response to gefitinib compared with common activating missense mutations. Mol Cancer Ther. 2009; 8:2142–51.TamIYLeungELTinVPChuaDTSihoeADChengLCDouble EGFR mutants containing rare EGFR mutant types show reduced in vitro response to gefitinib compared with common activating missense mutationsMol Cancer Ther2009821425110.1158/1535-7163.MCT-08-121919671738Search in Google Scholar

[15]Wei Z, An T, Wang Z, Chen K, Bai H, Zhu G, et al. Patients harboring epidermal growth factor receptor (EGFR) double mutations had a lower objective response rate than those with a single mutation in non-small cell lung cancer when treated with EGFR-tyrosine kinase inhibitors. Thorac Cancer. 2014; 5:126–32.WeiZAnTWangZChenKBaiHZhuGPatients harboring epidermal growth factor receptor (EGFR) double mutations had a lower objective response rate than those with a single mutation in non-small cell lung cancer when treated with EGFR-tyrosine kinase inhibitorsThorac Cancer201451263210.1111/1759-7714.12068470432326766989Search in Google Scholar

[16]Sonobe M, Manabe T, Wada H, Tanaka F. Mutations in the epidermal growth factor receptor gene are linked to smoking-independent, lung adenocarcinoma. Br J Cancer. 2005; 93:355–63.SonobeMManabeTWadaHTanakaFMutations in the epidermal growth factor receptor gene are linked to smoking-independent, lung adenocarcinomaBr J Cancer2005933556310.1038/sj.bjc.6602707236157016052218Search in Google Scholar